Strengthening Leadership with New Appointment:
Sphere Fluidics, a renowned provider of microfluidics-based solutions for single-cell analysis and isolation, has announced the appointment of Edward Rayner to its Board of Directors as a Non-Executive Director. This strategic move aims to leverage Rayner’s extensive expertise in fundraising and investment within the life sciences and technology sectors to drive the company’s growth and commercial success. His appointment reflects Sphere Fluidics’ commitment to enhancing its leadership team and advancing its ambitious plans for future expansion.
A Wealth of Experience:
Edward Rayner brings a wealth of experience from his distinguished career in the investment and biotech sectors. Having held key positions at leading research-led investment firms and biotech venture capital funds, including AMP Capital, Alliance Bernstein, and Arix Bioscience, Rayner has demonstrated his proficiency in managing equity portfolios, leading research teams, and launching successful small company funds. His background in healthcare and technology, combined with his expertise in fundraising and investment, makes him a valuable addition to the Sphere Fluidics team.
Excitement for Future Growth:
Dr. Frank F. Craig, CEO of Sphere Fluidics, expressed his delight at Edward Rayner joining the Board, citing Rayner’s international investment banking background and experience in leading investment funds as assets that will help shape the company’s growth trajectory and competitive positioning. Rayner himself is enthusiastic about his new role and looks forward to supporting Sphere Fluidics as it accelerates its commercial rollout. With a groundbreaking suite of products developed by the company’s multidisciplinary science and engineering teams, Rayner believes Sphere Fluidics is poised to make a significant impact on drug development programs, paving the way for future success.
